604 related articles for article (PubMed ID: 26695153)
1. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
3. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
4. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
5. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
6. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
8. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
9. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
10. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
11. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Hang J; Hu H; Huang J; Han T; Zhuo M; Zhou Y; Wang L; Wang Y; Jiao F; Wang L
Oncotarget; 2016 May; 7(19):28207-17. PubMed ID: 27057636
[TBL] [Abstract][Full Text] [Related]
12. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
16. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
18. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis.
Huang Y; Zheng J; Tan T; Song L; Huang S; Zhang Y; Lin L; Liu J; Zheng P; Chen X; Chen X; Ouyang X
Int J Biol Markers; 2018 May; 33(2):189-194. PubMed ID: 29076521
[TBL] [Abstract][Full Text] [Related]
19. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
[TBL] [Abstract][Full Text] [Related]
20. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.
Shi J; Guan X; Zhan F; Liu C; Li Z; Yao Y; Wang B; Lou C; Zhang Y
Cancer Biol Ther; 2019; 20(9):1290-1299. PubMed ID: 31311398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]